99694076
Mar 10, 2026
Pharmaceutical and veterinary preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome
Pharmaceuticals